Novo Nordisk, Eli Lilly fall after Trump comments on weight loss drug pricing
Joseph Loscalzo, a director at IONIS PHARMACEUTICALS INC (NASDAQ:IONS), sold 16,000 shares of common stock on September 3, 2025, for approximately $962,371. The shares were sold at prices ranging from $60.00 to $60.57, near the stock’s 52-week high of $62.08. InvestingPro data shows the stock has surged 75.85% over the past six months, with its market capitalization now reaching $9.47 billion.
On the same day, Loscalzo also exercised options to acquire 16,000 shares of Ionis Pharmaceuticals’ common stock at a price of $24.42, for a total value of $390,720.
Following these transactions, Loscalzo directly owns 36,330 shares of the company.
The sale was executed under a Rule 10b5-1 trading plan adopted on August 13, 2024.
In other recent news, Ionis Pharmaceuticals has reported significant developments that have captured investor attention. The company announced positive topline results from its Phase 3 CORE and CORE2 trials for severe hypertriglyceridemia, showing statistically significant benefits in triglyceride lowering and reducing acute pancreatitis risk. These results led Bernstein SocGen Group to describe the outcome as surpassing high expectations. Following these announcements, H.C. Wainwright raised its price target for Ionis Pharmaceuticals from $70 to $95, maintaining a Buy rating due to the strong triglyceride reductions observed in the pivotal studies. Similarly, RBC Capital increased its price target to $80, citing the positive Phase III data for the company’s acute pancreatitis treatment. Oppenheimer also adjusted its price target from $78 to $81, maintaining an Outperform rating. Furthermore, BMO Capital upgraded Ionis Pharmaceuticals from Market Perform to Outperform, highlighting the potential of Olezarsen to become a blockbuster drug in the US market. These developments indicate a growing confidence among analysts in the company’s recent clinical trial successes.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.